Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Regeneron Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Regeneron Pharmaceuticals, Inc.’s stock price such as:

• Regeneron Pharmaceuticals, Inc.’s current stock price and volume
• Why Regeneron Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for REGN from analysts
• REGN’s stock price momentum as measured by its relative strength

About Regeneron Pharmaceuticals, Inc. (REGN)

Before we jump into Regeneron Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Want to learn more about Regeneron Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 12:32 PM, CST, Regeneron Pharmaceuticals, Inc.’s stock price was $641.865.

Regeneron Pharmaceuticals, Inc. is down 1.22% from its previous closing price of $649.760.

During the last market session, Regeneron Pharmaceuticals, Inc.’s stock traded between $640.345 and $650.320. Currently, there are approximately 104.00 million shares outstanding for Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 15.8, which is low compared to the Biotechnology industry median of 18.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Regeneron Pharmaceuticals, Inc. Stock Price History

Regeneron Pharmaceuticals, Inc.’s (REGN) price is currently down 9.22% so far this month.

During the month of May, Regeneron Pharmaceuticals, Inc.’s stock price has reached a high of $730.590 and a low of $610.600.

Over the last year, Regeneron Pharmaceuticals, Inc. has hit prices as high as $821.110 and as low as $476.487. Year to date, Regeneron Pharmaceuticals, Inc.’s stock is down 16.84%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Regeneron Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were 2 analysts who downgraded Regeneron Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Regeneron Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Regeneron Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Regeneron Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Regeneron Pharmaceuticals, Inc. (REGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Regeneron Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Regeneron Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -6.83%, which translates to a Momentum Score of 37 and is considered to be Weak.

Want to learn more about how Regeneron Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Regeneron Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 21, 2026, Regeneron Pharmaceuticals, Inc.’s stock price is $641.865, which is down 1.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Regeneron Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.